AJP - Heart Fuel your research with LabChart
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


Am J Physiol Heart Circ Physiol 294: H1398-H1406, 2008. First published January 25, 2008; doi:10.1152/ajpheart.91438.2007
0363-6135/08 $8.00
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
294/3/H1398    most recent
ajpheart.91438.2007v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via ISI Web of Science (1)
Google Scholar
Right arrow Articles by Salloum, F. N.
Right arrow Articles by Kukreja, R. C.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Salloum, F. N.
Right arrow Articles by Kukreja, R. C.

Sildenafil (Viagra) attenuates ischemic cardiomyopathy and improves left ventricular function in mice

Fadi N. Salloum, Antonio Abbate, Anindita Das, Jon-Erik Houser, Colin A. Mudrick, Ian Z. Qureshi, Nicholas N. Hoke, Sion K. Roy, William R. Brown, Shashi Prabhakar, and Rakesh C. Kukreja

Division of Cardiology, Department of Internal Medicine, Virginia Commonwealth University, Richmond, Virginia

Submitted 11 December 2007 ; accepted in final form 14 January 2008

We tested the hypothesis that chronic treatment with sildenafil attenuates myocardial infarction (MI)-induced heart failure. Sildenafil has potent protective effects against necrosis and apoptosis following ischemia-reperfusion in the intact heart and cardiomyocytes. ICR mice underwent MI by left anterior descending coronary artery ligation and were treated with sildenafil (0.71 mg/kg bid) or saline for 4 wk. Infarct size (IS) was measured 24 h postinfarction, and apoptosis was measured by terminal deoxynucleotidyl transferase-mediated dUTP nick-end labeling. Left ventricular end-diastolic diameter (LVEDD) and fractional shortening (FS) were measured by echocardiography. Sildenafil reduced IS (40.0 ± 4.6%) compared with that in saline (69.6 ± 4.1%, P < 0.05). NG-nitro-L-arginine methyl ester, a nitric oxide synthase (NOS) inhibitor (15 mg/kg bid), blocked the protective effect of sildenafil (IS, 60.2 ± 1.6%, P < 0.05 vs. sildenafil). Western blot analysis revealed a significant increase in endothelial NOS/inducible NOS proteins 24 h post-MI after treatment with sildenafil versus saline. Apoptosis decreased from 2.4 ± 0.3% with saline to 1.2 ± 0.1% with sildenafil (P < 0.05) on day 7 and from 2.0 ± 0.2% with saline to 1.2 ± 0.1% with sildenafil on day 28 (P < 0.05), which was associated with an early increase in the Bcl-2-to-Bax ratio. LVEDD increased from baseline value of 3.6 ± 0.1 to 5.2 ± 0.2 and to 5.5 ± 0.1 mm on days 7 and 28, respectively, with saline (P < 0.05) but was attenuated to 4.4 ± 0.2 and 4.4 ± 0.1 mm following sildenafil treatment on days 7 and 28, respectively (P > 0.05 vs. baseline). FS significantly improved post-MI with sildenafil. A marked decline in cardiac hypertrophy was observed with sildenafil, which paralleled a reduction in pulmonary edema. Survival rate was lower with saline (36%) compared with sildenafil (93%, P < 0.05). Sildenafil attenuates ischemic cardiomyopathy in mice by limiting necrosis and apoptosis and by preserving left ventricular function possibly through a nitric oxide-dependent pathway.

phosphodiesterase inhibitors; heart failure; ischemic injury; vasodilatation; nitric oxide; guanosine 3',5'-cyclic monophosphate; apoptosis; remodeling



Address for reprint requests and other correspondence: R. C. Kukreja, Div. of Cardiology, Box 980281, Virginia Commonwealth Univ., 1101 E. Marshall St., Rm. 7-046, Richmond, VA 23298 (e-mail: rakesh{at}vcu.edu)




This article has been cited by other articles:


Home page
CirculationHome page
A. Abbate, F. N. Salloum, E. Vecile, A. Das, N. N. Hoke, S. Straino, G. G.L. Biondi-Zoccai, J.-E. Houser, I. Z. Qureshi, E. D. Ownby, et al.
Anakinra, a Recombinant Human Interleukin-1 Receptor Antagonist, Inhibits Apoptosis in Experimental Acute Myocardial Infarction
Circulation, May 20, 2008; 117(20): 2670 - 2683.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Visit Other APS Journals Online
Copyright © 2008 by the American Physiological Society.